‘European research networks to facilitate drug research in children’ has been published in the British Journal of Clinical Pharmacology. Paediatric drug development faces several barriers. These include fragmentation of stakeholders and inconsistent processes during the conduct of research. This review summarises recent efforts to overcome these barriers in Europe. Two exemplar initiatives are described.…
DetailsIn a conventional clinical trial, adult or paediatric, typically half of the participants receive the drug under investigation and half receive placebo or standard of care. If there are many trials in a disease area, it can be hard to find enough patients for all the trials taking place at a given time. Trials may…
Details“The conect4children (c4c) Consortium: Potential for Improving European Clinical Research into Medicines for Children” has been published in Pharmaceutical Medicine. Clinical trial scientists and their teams, for several decades, have partially succeeded in improving ways on how paediatric trials are conducted. In 2007, the European Union recognised the need to facilitate development of medicines…
Details“Path towards efficient paediatric formulation development based on partnering with clinical pharmacologists and clinicians, a c4c expert group White paper” has been published by British Journal of Clinical Pharmacology. Despite regulatory requirements and incentives, paediatric formulations still lag behind adult formulations for medicines used in both adults and children. This is largely due to…
DetailsRelated posts: How c4c is improving European paediatric clinical research through partnerships European research networks to facilitate drug research in children Improving clinical paediatric research using lessons learnt from COVID-19 Health Technology Assessment of Paediatric Medicines
Details
